28 - 30 September 2016, Brac, Croatia

Course Objectives

This course will be devoted to the management of difficult-to-treat mycobacterial infections including MDR- and XDR-TB and emergent non-tuberculous mycobacteria (NTM) infections such as those due to M. abscessus, M. chelonae and M. chimaera. The different problems in diagnosing and treating these infections will be analyzed from the technical and organizational aspects including the setting of interprofessional consilium. Clinical microbiologists and physicians specialized in mycobacterial infections will present the specific strategies followed in various epidemiological settings.

Course Venue

Hoteli Svpetrvs (Waterman resorts)
Put Vele luke 4
21400 Supetar, Island of Brac, Croatia

Phone +00 385 (0) 21 631 133
Fax +00 385 (0)21 631 344
info[at]watermanresorts.com
www.svpetrvs.com

Target Audience

Up to 50 clinical microbiologists of routine and expert labs involved in drug resistance investigation, physicians in charge of patients suffering from MDRTB or emergent NTM infections, public health officers involved in TB control and surveillance, or in health-acquired infections (HAI) due to NTM.

CME Accreditation

The organizers of the course will apply for European CME accreditation through EACCME.

Contact Person (Scientific Programme)

Vincent Jarlier
Laboratoire de Bacteriologie
Hopital Pitié-Salpêtrière
47, boulevard de l’hôpital
75013 Paris
France

Phone +33 142 162 070
Vincent.jarlier[at]aphp.fr

Administrative Secretariat

Mateja Jankovic
University Hospital Center Zagreb
Department for Respiratory Diseases
Jordanovac 104
10000 Zagreb
Croatia

Phone +385 98 812 622
mateja.jankovic[at]gmail.com

Presentations are availabe in the ESCMID Online Lecture Library.

Diagnosis of MDR-TB

• Direct bacteriological TB diagnosis
• Antituberculous agents: mechanisms of action and resistance
• Rapid genotypic detection of resistance
• Whole genome sequencing for detection of resistance traits
• Phenotypic testing for second line antituberculous agents
• Strategies for the detection of multidrug resistance

Treatment and management of MDR-TB

• Second line antituberculous agents: principles for use
• Principles for MDR-TB treatment design
• Residual activity of antituberculous agents on strains with resistant traits
• Concept, principles and practice of TB consilium for personalized treatment
• Outcome endpoints and follow-up of patients treated for MDR-TB
• Prevention of side effects and toxicity
• Recurrent and chronic cases
• Specific populations: migrants, co-infections

Prevention of MDR-TB in population-based conditions

• Prevention of MDR-TB cross-transmission
• Chemoprophylaxis
• Immunity-based prevention and diagnosis
• Biosafety and security
• Challenges for the TB reference labs (setup, accreditation, management)
• Surveillance of MDR-TB: from region to Europe
• Molecular tools for MDR-TB epidemiology

Multi-resistant non-tuberculous mycobacteria (NTM)

• Difficult-to-treat NTM community-acquired infections
• Difficult-to-treat NTM health care-associated infections
• NTM and risks of infections associated with trend behaviour and lifestyle

• Emmanuelle Cambau, Paris, France
• Charles Daley, Denver, CO, United States
• Jon Friedland, London, United Kingdom
• Delia Goletti, Rome, Italy
• Lorenzo Guglielmetti, Verona, Italy
• Mateja Jankovic, Zagreb, Croatia
• Vincent Jarlier, Paris, France
• Vera Katalinic-Jankovic, Zagreb, Croatia
• Tanil Kocagoz, Istanbul, Turkey
• Christoph Lange, Borstel, Germany
• Alberto Matteelli, Brescia, Italy
• Marc Mendelson, Cape Town, South Africa
• Mark Nicol, Cape Town, South Africa
• Dimitrios Papaventsis, Athens, Greece
• Cristina Popa, Bucharest, Romania
• Francesca Sanchez, Barcelona, Spain
• Miguel Santin, Barcelona, Spain
• Thomas Schon, Linköping, Sweden
• Wladimir Sougakoff, Paris, France
• Jakko Van Ingen, Nijmegen, Netherlands
• Nicolas Veziris, Paris, France
• Miguel Viveiros, Lisbon, Portugal
• Dirk Wagner, Freiburg, Germany
• Christian Weijse, Aarhus, Denmark
• Ljiljana Zmak, Zagreb, Croatia